T1	Participants 269 325	patients with EGFR mutation-positive lung adenocarcinoma
T2	Participants 432 505	patients with EGFR mutation-positive stage IIIB or IV lung adenocarcinoma
T3	Participants 572 841	patients were randomly assigned in a 2:1 ratio to receive afatinib or chemotherapy (pemetrexed-cisplatin [LUX-Lung 3] or gemcitabine-cisplatin [LUX-Lung 6]), stratified by EGFR mutation (exon 19 deletion [del19], Leu858Arg, or other) and ethnic origin (LUX-Lung 3 only)
T4	Participants 921 931	population
T5	Participants 1163 1184	345 patients had died
T6	Participants 1257 1278	364 patients had died
T7	Participants 1411 1437	pemetrexed-cisplatin group
T8	Participants 1606 1633	gemcitabine-cisplatin group
T9	Participants 1361 1375	afatinib group
T10	Participants 1556 1570	afatinib group
T11	Participants 1750 1839	patients with del19-positive tumours in the afatinib group than in the chemotherapy group
T12	Participants 1937 1951	afatinib group
T13	Participants 1990 2008	chemotherapy group
T14	Participants 2258 2303	patients with EGFR Leu858Arg-positive tumours
T15	Participants 2391 2475	the afatinib group versus 40.3 months (24.3-not estimable) in the chemotherapy group
T16	Participants 2753 2765	229 patients
T17	Participants 2753 2820	229 patients in LUX-Lung 3 and 35 [15%] of 239 patients in LUX-Lung
T18	Participants 3353 3393	overall survival in the whole population
T19	Participants 3459 3493	patients with del19 EGFR mutations
T20	Participants 3523 3561	patients with Leu858Arg EGFR mutations
